CS1 Targeted CAR-T Cells (MB-104) for the Treatment of Multiple Myeloma Shows Antitumor Activity Sparing Normal T-Cells Despite the Common Expression of CS1

被引：0
|
作者：
Gumlaw, Nathan [1 ]
Joseph, Aviva [1 ]
Edinger, James [1 ]
Patel, Ekta [1 ]
机构：
[1] Mustang Bio, Res & Dev, Worcester, MA USA
来源：
MOLECULAR THERAPY | 2020年 / 28卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
421
引用
收藏
页码：189 / 190
页数：2
相关论文
共 37 条
  • [21] A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients
    J Bae
    R Prabhala
    A Voskertchian
    A Brown
    C Maguire
    P Richardson
    G Dranoff
    K C Anderson
    N C Munshi
    Leukemia, 2015, 29 : 218 - 229
  • [22] A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients
    Bae, J.
    Prabhala, R.
    Voskertchian, A.
    Brown, A.
    Maguire, C.
    Richardson, P.
    Dranoff, G.
    Anderson, K. C.
    Munshi, N. C.
    LEUKEMIA, 2015, 29 (01) : 218 - 229
  • [23] Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study
    Li, Chenggong
    Wang, Xindi
    Wu, Zhuolin
    Luo, Wenjing
    Zhang, Yinqiang
    Kang, Yun
    Xu, Jia
    Huang, Zhongpei
    Du, Mengyi
    Tang, Lu
    Wu, Jianghua
    Liao, Danying
    Kou, Haiming
    Lu, Cong
    Jiang, Huiwen
    Wei, Qiuzhe
    Ke, Sha
    Zheng, Jing'e
    Xiong, Wei
    Deng, Jun
    Hu, Yu
    Mei, Heng
    BLOOD, 2022, 140 : 4573 - 4574
  • [24] Daratumumab combined with CD38(-) natural killer cells armed with a CS1 chimeric antigen receptor for the treatment of relapsed multiple myeloma
    Wang, Yufeng
    Zhang, Yibo
    Bnson, Don
    Caligiuri, Michael
    Yu, Jianhua
    CANCER RESEARCH, 2017, 77
  • [25] Chemotherapeutic drugs induce expression of CS1 (CD319) in multiple myeloma cells resulting in enhanced NK cell mediated killing.
    Malaer, Joseph D.
    Mathew, Porunelloor A.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [26] Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma
    Korst, Charlotte L. B. M.
    O'Neill, Chloe
    Bruins, Wassilis S. C.
    Cosovic, Meliha
    Twickler, Inoka
    Verkleij, Christie P. M.
    Le Clerre, Diane
    Themeli, Maria
    Chion-Sotinel, Isabelle
    Zweegman, Sonja
    Galetto, Roman
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07)
  • [27] DCLK1 monoclonal antibody-based CAR-T cells as novel treatment strategy against multiple myeloma
    Sureban, Sripathi M.
    Berahovich, Robert
    Zhou, Hua
    Xu, Shirley
    Wu, Lijun
    Golubovskaya, Vita
    Qu, Dongfeng
    May, Randal
    Bannerman-Menson, Edwin
    Houchen, Courtney W.
    CANCER RESEARCH, 2019, 79 (13)
  • [28] CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered NK Cells and T Cells Enhance In Vitro and In Vivo Anti-Tumor Activity Against Human Multiple Myeloma
    Chu, Jianhong
    Deng, Youcai
    Benson, Don M., Jr.
    He, Shun
    Hughes, Tiffany L.
    Zhang, Jianying
    Peng, Yong
    Mao, Hsiaoyin
    Yi, Ling
    He, Xiaoming
    Devine, Steven M.
    Zhang, Xiaoliu
    Caligiuri, Michael A.
    Hofmeister, Craig C.
    Yu, Jianhua
    BLOOD, 2013, 122 (21)
  • [29] Engineered T cells modified to express a CS-1-specific CAR confer anti-myeloma activity in vitro and in preclinical in vivo models
    Gogishvili, T.
    Danhof, S.
    Sommermeyer, D.
    Brede, C.
    Beilhack, A.
    Kunzmann, V.
    Einsele, H.
    Hudecek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 202 - 202
  • [30] GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma
    Sun, Rui-xin
    Liu, Yi-fan
    Sun, Yan-sha
    Zhou, Min
    Wang, Yi
    Shi, Bi-zhi
    Jiang, Hua
    Li, Zong-hai
    ACTA PHARMACOLOGICA SINICA, 2024, 45 (09) : 1937 - 1950
1234